Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1985 1
1986 1
1987 3
1988 3
1989 3
1990 2
1991 3
1992 1
1993 3
1994 7
1995 6
1996 4
1997 3
1998 5
1999 5
2000 6
2001 1
2002 5
2003 5
2004 3
2005 7
2006 8
2007 9
2008 6
2009 10
2010 6
2011 9
2012 14
2013 15
2014 14
2015 12
2016 21
2017 10
2018 15
2019 18
2020 17
2021 11
2022 16
2023 16
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

289 results

Results by year

Filters applied: . Clear all
Page 1
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin EC, Grinsted L, Schiavon G, Foxley A, Rugo HS; CAPItello-291 Study Group. Turner NC, et al. N Engl J Med. 2023 Jun 1;388(22):2058-2070. doi: 10.1056/NEJMoa2214131. N Engl J Med. 2023. PMID: 37256976 Clinical Trial.
Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, Tan DSW, Hida T, de Jonge M, Orlov SV, Smit EF, Souquet PJ, Vansteenkiste J, Hochmair M, Felip E, Nishio M, Thomas M, Ohashi K, Toyozawa R, Overbeck TR, de Marinis F, Kim TM, Laack E, Robeva A, Le Mouhaer S, Waldron-Lynch M, Sankaran B, Balbin OA, Cui X, Giovannini M, Akimov M, Heist RS; GEOMETRY mono-1 Investigators. Wolf J, et al. N Engl J Med. 2020 Sep 3;383(10):944-957. doi: 10.1056/NEJMoa2002787. N Engl J Med. 2020. PMID: 32877583 Clinical Trial.
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F; PROFILE 1014 Investigators. Solomon BJ, et al. N Engl J Med. 2014 Dec 4;371(23):2167-77. doi: 10.1056/NEJMoa1408440. N Engl J Med. 2014. PMID: 25470694 Free article. Clinical Trial.
Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis.
Siciliano MA, Caridà G, Ciliberto D, d'Apolito M, Pelaia C, Caracciolo D, Riillo C, Correale P, Galvano A, Russo A, Barbieri V, Tassone P, Tagliaferri P. Siciliano MA, et al. Among authors: tagliaferri p. ESMO Open. 2022 Jun;7(3):100465. doi: 10.1016/j.esmoop.2022.100465. Epub 2022 Apr 12. ESMO Open. 2022. PMID: 35427835 Free PMC article.
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer.
Riillo C, Polerà N, Di Martino MT, Juli G, Hokanson CA, Odineca T, Signorelli S, Grillone K, Ascrizzi S, Mancuso A, Staropoli N, Caparello B, Cerra M, Nisticò G, Tagliaferri P, Crea R, Caracciolo D, Tassone P. Riillo C, et al. Among authors: tagliaferri p. J Transl Med. 2023 May 4;21(1):301. doi: 10.1186/s12967-023-04101-x. J Transl Med. 2023. PMID: 37143061 Free PMC article.
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma.
Scionti F, Juli G, Rocca R, Polerà N, Nadai M, Grillone K, Caracciolo D, Riillo C, Altomare E, Ascrizzi S, Caparello B, Cerra M, Arbitrio M, Richter SN, Artese A, Alcaro S, Tagliaferri P, Tassone P, Di Martino MT. Scionti F, et al. Among authors: tagliaferri p. J Exp Clin Cancer Res. 2023 Mar 27;42(1):71. doi: 10.1186/s13046-023-02633-0. J Exp Clin Cancer Res. 2023. PMID: 36967378 Free PMC article.
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study.
Tassone P, Di Martino MT, Arbitrio M, Fiorillo L, Staropoli N, Ciliberto D, Cordua A, Scionti F, Bertucci B, Salvino A, Lopreiato M, Thunarf F, Cuomo O, Zito MC, De Fina MR, Brescia A, Gualtieri S, Riillo C, Manti F, Caracciolo D, Barbieri V, Di Paola ED, Di Francesco AE, Tagliaferri P. Tassone P, et al. Among authors: tagliaferri p. J Hematol Oncol. 2023 Jun 26;16(1):68. doi: 10.1186/s13045-023-01468-8. J Hematol Oncol. 2023. PMID: 37365583 Free PMC article. Clinical Trial.
The Non-Coding RNA Landscape of Plasma Cell Dyscrasias.
Morelli E, Gullà A, Rocca R, Federico C, Raimondi L, Malvestiti S, Agosti V, Rossi M, Costa G, Giavaresi G, Azab KA, Cagnetta A, Cea M, Tagliaferri P, Neri A, Munshi NC, Viglietto G, Tassone P, Amodio N. Morelli E, et al. Among authors: tagliaferri p. Cancers (Basel). 2020 Jan 30;12(2):320. doi: 10.3390/cancers12020320. Cancers (Basel). 2020. PMID: 32019064 Free PMC article. Review.
The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review.
Nardone V, Romeo C, D'Ippolito E, Pastina P, D'Apolito M, Pirtoli L, Caraglia M, Mutti L, Bianco G, Falzea AC, Giannicola R, Giordano A, Tagliaferri P, Vinciguerra C, Desideri I, Loi M, Reginelli A, Cappabianca S, Tassone P, Correale P. Nardone V, et al. Among authors: tagliaferri p. Radiol Med. 2023 Mar;128(3):316-329. doi: 10.1007/s11547-023-01602-z. Epub 2023 Feb 14. Radiol Med. 2023. PMID: 36786970 Free PMC article. Review.
The impact of PARP inhibitors in the whole scenario of ovarian cancer management: A systematic review and network meta-analysis.
Staropoli N, Ciliberto D, Luciano F, Napoli C, Costa M, Rossini G, Arbitrio M, Labanca C, Riillo C, Del Giudice T, Crispino A, Salvino A, Galvano A, Russo A, Tassone P, Tagliaferri P. Staropoli N, et al. Among authors: tagliaferri p. Crit Rev Oncol Hematol. 2024 Jan;193:104229. doi: 10.1016/j.critrevonc.2023.104229. Epub 2023 Dec 7. Crit Rev Oncol Hematol. 2024. PMID: 38065404 Free article. Review.
289 results